At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 10, 2026 at 16:27 ET
Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the board from 7 to 8 members. This is a routine governance change with no financial impact or strategic implications disclosed.
- Board expanded from 7 to 8 members; Timothy Coughlin appointed to fill new vacancy
- Coughlin will serve as Class III director until 2028 annual meeting and as Audit Committee Chair
- No arrangement or understanding with any person triggered the appointment; no related party transactions
- Coughlin receives standard non-employee director compensation per existing policy, including stock option and RSU grants under the 2019 Equity Incentive Plan
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access